# Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A

> **NCT02572817** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 138 (actual)

## Conditions studied

- Influenza A Virus Infection

## Interventions

- **BIOLOGICAL:** High-titer anti-influenza plasma
- **BIOLOGICAL:** Low-titer anti-influenza plasma

## Key facts

- **NCT ID:** NCT02572817
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2018-04-26
- **Final completion:** 2018-05-18
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2019-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02572817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02572817, "Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02572817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*